↓ Skip to main content

Michigan Publishing

Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment

Overview of attention for article published in American Journal of Preventive Medicine, June 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
18 news outlets
blogs
2 blogs
policy
2 policy sources
twitter
9 X users
facebook
1 Facebook page

Citations

dimensions_citation
191 Dimensions

Readers on

mendeley
255 Mendeley
Title
Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment
Published in
American Journal of Preventive Medicine, June 2018
DOI 10.1016/j.amepre.2017.12.022
Pubmed ID
Authors

Rebecca L. Haffajee, Amy S.B. Bohnert, Pooja A. Lagisetty

Abstract

At least 2.3 million people in the U.S. have an opioid use disorder, less than 40% of whom receive evidence-based treatment. Buprenorphine used as part of medication-assisted treatment has high potential to address this gap because of its approval for use in non-specialty outpatient settings, effectiveness at promoting abstinence, and cost effectiveness. However, less than 4% of licensed physicians are approved to prescribe buprenorphine for opioid use disorder, and approximately 47% of counties lack a buprenorphine-waivered physician. Existing policies contribute to workforce barriers to buprenorphine provision and access. Providers are reticent to prescribe buprenorphine because of workforce barriers, such as (1) insufficient training and education on opioid use disorder treatment, (2) lack of institutional and clinician peer support, (3) poor care coordination, (4) provider stigma, (5) inadequate reimbursement from private and public insurers, and (6) regulatory hurdles to obtain the waiver needed to prescribe buprenorphine in non-addiction specialty treatment settings. Policy pathways to addressing these provider workforce barriers going forward include providing free and easy-to-access education for providers about opioid use disorders and medication-assisted treatment, eliminating buprenorphine waiver requirements for those licensed to prescribe controlled substances, enforcing insurance parity requirements, requiring coverage of evidence-based medication-assisted treatment as essential health benefits, and providing financial incentives for care coordination across healthcare professional types-including behavioral health counselors and other non-physicians in specialty and non-specialty settings. This article is part of a supplement entitled The Behavioral Health Workforce: Planning, Practice, and Preparation, which is sponsored by the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration of the U.S. Department of Health and Human Services.

X Demographics

X Demographics

The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 255 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 255 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 44 17%
Student > Master 34 13%
Student > Ph. D. Student 23 9%
Student > Doctoral Student 22 9%
Other 17 7%
Other 44 17%
Unknown 71 28%
Readers by discipline Count As %
Medicine and Dentistry 44 17%
Social Sciences 35 14%
Nursing and Health Professions 32 13%
Psychology 19 7%
Pharmacology, Toxicology and Pharmaceutical Science 8 3%
Other 33 13%
Unknown 84 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 171. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2022.
All research outputs
#237,293
of 25,503,365 outputs
Outputs from American Journal of Preventive Medicine
#293
of 5,283 outputs
Outputs of similar age
#5,187
of 343,115 outputs
Outputs of similar age from American Journal of Preventive Medicine
#8
of 63 outputs
Altmetric has tracked 25,503,365 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,283 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 41.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,115 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.